Results 31 to 40 of about 262,029 (244)

Efficacy and safety of neoadjuvant systemic therapy in resectable hepatocellular carcinoma: a Systematic Review and meta-analysis

Frontiers in Oncology
BackgroundNeoadjuvant systemic therapy has been shown to benefit patients with solid tumors such as breast cancer and colorectal cancer, but its application in hepatocellular carcinoma (HCC) is still in the exploratory stage, with no established ...
Dongdong Wu, Ning Liu, Hao Dong, Kan Zhou, Lei Du, Ying Li, Yanjun Chao, Fuping Ma   +7 more
doaj   +1 more source

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion

Indian Journal of Urology, 2012
Introduction: Chemotherapy was shown to improve survival in patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The initiation and completion rates for perioperative chemotherapy are variable.
Ahmed Eldefrawy, Mark S Soloway, Devendar Katkoori, Rakesh Singal, David Pan, Murugesan Manoharan   +5 more
doaj   +1 more source

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer

OncoImmunology, 2021
This review details the clinical utility of Immunoscore, measuring the immune response to cancer within the tumor microenvironment, in bladder cancer. Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for gastrointestinal cancer ...
Elise F. Nassif, Constance Thibault, Stéphane Oudard, Jérôme Galon   +3 more
doaj   +1 more source

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

Current Oncology, 2022
Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options have existed for this subtype of breast cancer, with cytotoxic chemotherapy ...
Isaiah MacDonald, Nancy A. Nixon, Omar F. Khan   +2 more
doaj   +1 more source

DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma : a preliminary report [PDF]

, 2018
Purpose: Neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables evaluation of the tumour neovasculature that occurs prior to any volume change, which
Fotedar, Vikas, Seam, Rajeev K., Sharma, Anjna, Sharma, Mukesh, Sharma, Sanjiv, Sood, Shikha   +5 more
core   +1 more source

Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study

ESMO Real World Data and Digital Oncology
Background: The aim of the study was to compare trastuzumab-based neoadjuvant therapy (NAT) with adjuvant therapy (AT) in a register-based cohort of Swedish patients with primary operable human epidermal growth factor receptor 2 (HER2)-positive breast ...
S. Hosseini-Mellner, Å. Wickberg, E. Olsson, A. Karakatsanis, A. Valachis   +4 more
doaj   +1 more source

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer

Frontiers in Immunology, 2022
Breast cancer (BC) is the most prevalent cancer in women worldwide. A systematic approach to BC treatment, comprising adjuvant and neoadjuvant chemotherapy (NAC), as well as hormone therapy, forms the foundation of the disease’s therapeutic strategy. The
Jianyu Liu, Bo Lei, Xin Yu, Yingpu Li, Yuhan Deng, Guang Yang, Zhigao Li, Tong Liu, Leiguang Ye   +8 more
doaj   +1 more source

Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer [PDF]

, 2017
This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic method for quantitative assessment of the percentage of fibrosis developed within locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). A total
Bellini, D, Caruso, D, Caterino, Martina, Ciolina, M, De Santis, D, Laghi, A., Marzi, S, Musio, Daniela, Picchia, S, Rengo, M, Tombolini, V   +10 more
core   +1 more source

Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
Objective To evaluate the safety, feasibility and efficacy of template-assisted 192Ir-based hypofractionated stereotactic ablative brachytherapy (SABT) combined with surgery for peripheral non-small cell lung cancer (NSCLC) patients.
SHI Xiangxiang, PANG Haowen, SUN Xiaoyang, REN Peirong, WU Jingbo, LIN Sheng   +5 more
doaj   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core